Click Here to return To Results

 

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Pts with AIDS Ann Int Med 115:665-673, Palestine,A.G.,et al, 1991 See this aricle in Pubmed Article Abstract The mean time to progression of retinitis was 3.2 weeks in the control group(n=11)compared with 13.3 weeks in the treatment group(n=13)(P<0.001). Nine of 13 patients in the treatment group had positive blood cultures for cytomegalovirus at entry and all nine cleared their blood of cytomegalovirus by the end of the induction period(P=0.004)compared with one of six patients in the control group.No reduction in p24 levels were seen in the control patients compared with a reduction of more than 50%in p24 levels for all four patients on treatment for whom follow-up levels were available.The main adverse effects of foscarnet treatment were seizures(2 of 13 patients),hypomagnesemia(9 of 13),hypocalcemia(11 of 13), and elevations in serum creatinine above 176.8 umol/L(2.0 mg/dL)(3 of 13). The control patients received an average of 0.2 units of blood per week compared with an average of 0.6 units of blood per week for the patients on treatment.The administration of foscarnet decreases the rate of progression of cytomegalovirus retinitis in persons with AIDS.Its judicious use is likely to prevent loss of vision in these patients.In this study,however,there was little change in visual acuity in patients in either the immediate or delayed treatment group because only patients with non-sight-threatening disease were selected.

Related Tags

(click to filter results - removes previous filter) acquired immunodeficiency syndrome adverse drug reaction chorioretinitis creatinine,elevated cytomegalovirus infection foscarnet fundus,abnormality of human immunodeficiency virus type 1 hypocalcemia hypomagnesemia retinal lesion retinopathy seizure seizure,drug-induced treatment of neurologic disorder visual loss

Click Here to return To Results